Elzayat M, Markofski M, Simpson R, Laughlin M, Lavoy E
Front Physiol. 2021; 12:713183.
PMID: 34456752
PMC: 8388854.
DOI: 10.3389/fphys.2021.713183.
Hermans D, Webby R, Wong S
J Thorac Dis. 2018; 10(Suppl 19):S2238-S2247.
PMID: 30116603
PMC: 6072921.
DOI: 10.21037/jtd.2017.12.122.
Peck K, Chan C, Tanaka M
Virus Evol. 2016; 1(1):vev013.
PMID: 27774285
PMC: 5014490.
DOI: 10.1093/ve/vev013.
Wang Z, Loh L, Kedzierski L, Kedzierska K
Front Immunol. 2016; 7:60.
PMID: 26973644
PMC: 4771736.
DOI: 10.3389/fimmu.2016.00060.
Mbawuike I, Atmar R, Patel S, Corry D, Winokur P, Brady R
Vaccine. 2015; 34(4):547-554.
PMID: 26657997
PMC: 4713282.
DOI: 10.1016/j.vaccine.2015.11.055.
Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset.
Kornum B, Pizza F, Knudsen S, Plazzi G, Jennum P, Mignot E
Brain Behav Immun. 2015; 49:54-8.
PMID: 25771509
PMC: 4567452.
DOI: 10.1016/j.bbi.2015.03.004.
Mathematical model of the primary CD8 T cell immune response: stability analysis of a nonlinear age-structured system.
Terry E, Marvel J, Arpin C, Gandrillon O, Crauste F
J Math Biol. 2011; 65(2):263-91.
PMID: 21842166
DOI: 10.1007/s00285-011-0459-8.
Influenza vaccine responses in older adults.
McElhaney J
Ageing Res Rev. 2010; 10(3):379-88.
PMID: 21055484
PMC: 3061971.
DOI: 10.1016/j.arr.2010.10.008.
Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.
McElhaney J
Aging health. 2009; 4(6):603-613.
PMID: 20011611
PMC: 2790215.
DOI: 10.2217/1745509X.4.6.603.
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
DiNapoli J, Nayak B, Yang L, Finneyfrock B, Cook A, Andersen H
J Virol. 2009; 84(3):1489-503.
PMID: 19923177
PMC: 2812327.
DOI: 10.1128/JVI.01946-09.
Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine.
Co M, Orphin L, Cruz J, Pazoles P, Rothman A, Ennis F
Vaccine. 2008; 26(16):1990-8.
PMID: 18339461
PMC: 2440689.
DOI: 10.1016/j.vaccine.2008.02.024.
Development of stable influenza vaccine powder formulations: challenges and possibilities.
Amorij J, Huckriede A, Wilschut J, Frijlink H, Hinrichs W
Pharm Res. 2008; 25(6):1256-73.
PMID: 18338241
PMC: 2346510.
DOI: 10.1007/s11095-008-9559-6.
Outcome of influenza vaccination in combat-related post-traumatic stress disorder (PTSD) patients.
Kosor Krnic E, Gagro A, Kozaric-Kovacic D, Vilibic M, Grubisic-Ilic M, Folnegovic-Smalc V
Clin Exp Immunol. 2007; 149(2):303-10.
PMID: 17511777
PMC: 1941948.
DOI: 10.1111/j.1365-2249.2007.03410.x.
Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.
Mbawuike I, Zang Y, Couch R
Vaccine. 2007; 25(17):3263-9.
PMID: 17280748
PMC: 2017113.
DOI: 10.1016/j.vaccine.2007.01.073.
Kinetics of influenza A virus infection in humans.
Baccam P, Beauchemin C, Macken C, Hayden F, Perelson A
J Virol. 2006; 80(15):7590-9.
PMID: 16840338
PMC: 1563736.
DOI: 10.1128/JVI.01623-05.
Repeated influenza vaccination of healthy children and adults: borrow now, pay later?.
Carrat F, Lavenu A, Cauchemez S, Deleger S
Epidemiol Infect. 2006; 134(1):63-70.
PMID: 16409652
PMC: 2870374.
DOI: 10.1017/S0950268805005479.
Assessment of markers of the cell-mediated immune response after influenza virus infection in frail older adults.
McElhaney J, Gravenstein S, Krause P, Hooton J, Upshaw C, Drinka P
Clin Diagn Lab Immunol. 1998; 5(6):840-4.
PMID: 9801346
PMC: 96213.
DOI: 10.1128/CDLI.5.6.840-844.1998.
Analysis of human antiviral cytotoxic T-lymphocyte responses for vaccine trials using cryopreserved mononuclear leukocytes: demonstration of feasibility with influenza virus-specific responses.
Nichols J, Roberts Jr N
Clin Diagn Lab Immunol. 1994; 1(5):487-92.
PMID: 8556490
PMC: 368318.
DOI: 10.1128/cdli.1.5.487-492.1994.
Influenza A virus replication is inhibited by tumor necrosis factor-alpha in vitro.
Campen H
Arch Virol. 1994; 136(3-4):439-46.
PMID: 8031247
DOI: 10.1007/BF01321073.
Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women.
Powers D
Clin Diagn Lab Immunol. 1994; 1(1):16-20.
PMID: 7496915
PMC: 368189.
DOI: 10.1128/cdli.1.1.16-20.1994.